<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03353740</url>
  </required_header>
  <id_info>
    <org_study_id>175518</org_study_id>
    <secondary_id>NCI-2018-00040</secondary_id>
    <nct_id>NCT03353740</nct_id>
  </id_info>
  <brief_title>Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence</brief_title>
  <official_title>Gallium-68 PSMA-11 PET Imaging in Patients With Biochemical Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Hope</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are imaging patients with prostate cancer using a new PET imaging agent
      (Ga-68-PSMA-11) in order to evaluate its ability to detection prostate cancer in patients
      with biochemical recurrence after prostatectomy and radiation therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 20, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location in prostate bed confirmed by histopathology/biopsy, clinical and conventional imaging follow-up.</measure>
    <time_frame>1 day</time_frame>
    <description>Point estimate of the sensitivity will be calculated with the corresponding 95% confidence interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location in pelvis outside of prostate bed including lymph nodes confirmed by histopathology/biopsy, clinical and conventional imaging follow-up.</measure>
    <time_frame>1 Day</time_frame>
    <description>Point estimate of the sensitivity will be calculated with the corresponding 95% confidence interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location in extrapelvic soft tissue, lymph nodes and organ metastases (non-bone) confirmed by histopathology/biopsy, clinical and conventional imaging follow-up.</measure>
    <time_frame>1 Day</time_frame>
    <description>Point estimate of the sensitivity will be calculated with the corresponding 95% confidence interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location in bone metastases confirmed by histopathology/biopsy, clinical and conventional imaging follow-up.</measure>
    <time_frame>1 Day</time_frame>
    <description>Point estimate of the sensitivity will be calculated with the corresponding 95% confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value (PPV) for detection of tumor location in prostate bed confirmed by histopathology/biopsy, clinical and conventional imaging follow-up.</measure>
    <time_frame>1 Day</time_frame>
    <description>Probability of a positive prediction calculated and reported with the corresponding two-sided 95% confidence intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PPV for detection of tumor location in pelvis outside of prostate bed including lymph nodes confirmed by histopathology/biopsy, clinical and conventional imaging follow-up.</measure>
    <time_frame>1 Day</time_frame>
    <description>Probability of a positive prediction calculated and reported with the corresponding two-sided 95% confidence intervals intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PPV on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location in extrapelvic soft tissue, lymph nodes and organ metastases (non-bone) confirmed by histopathology/biopsy, clinical and conventional imaging follow-up.</measure>
    <time_frame>1 Day</time_frame>
    <description>Probability of a positive prediction calculated and reported with the corresponding two-sided 95% confidence intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PPV on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location in bone metastases confirmed by histopathology/biopsy, clinical and conventional imaging follow-up.</measure>
    <time_frame>1 Day</time_frame>
    <description>Probability of a positive prediction calculated and reported with the corresponding two-sided 95% confidence intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection rates of 68Ga-PSMA-11 PET stratified by PSA value</measure>
    <time_frame>1 Day</time_frame>
    <description>Detection rates on a per-patient basis of 68Ga-PSMA-11 PET stratified by PSA value (0.2- &lt;0.5, 0.5 - &lt;1.0, 1.0 - &lt;2.0, 2.0 - &lt;5.0, &gt;=5.0) will be summarized in tabular format and compared between PSA strata using chi-square analysis. Detection rate is defined as number of patients with PSMA positive disease, independent of pathology, imaging or clinical follow-up. A detection rate will be reported for each reader independently stratified by PSA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of 68Ga-PSMA-11 PET on clinical management in patients with biochemical recurrence (BCR)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Evaluated using descriptive statistics based on qualitative physician responses from the change in management surveys</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-reader reproducibility for positivity</measure>
    <time_frame>1 Day</time_frame>
    <description>Inter-reader reproducibility for positivity at the patient level and region level will be reported using the Fleiss' Kappa test for multiple readers</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">345</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Ga-68 labeled PSMA-11 PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ga-68 labeled PSMA-11 PET</intervention_name>
    <description>Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.</description>
    <arm_group_label>Ga-68 labeled PSMA-11 PET</arm_group_label>
    <other_name>Ga-68 labeled DKFZ-PSMA-11</other_name>
    <other_name>Ga-68 labeled Glu-NH-CO-NH- Lys(Ahx)-HBED-CC</other_name>
    <other_name>Ga-68 labeled Glu-urea- Lys(Ahx)-HBED-CC</other_name>
    <other_name>Ga-68 labeled HBED-CC PSMA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Histopathologically proven prostate adenocarcinoma.

          -  Rising prostate-specific antigen (PSA) (at least two consecutive rising PSAs) after
             definitive therapy with prostatectomy or radiation therapy (external beam or
             brachytherapy).

               -  Post radical prostatectomy (RP) - American Urological Association (AUA)
                  recommendation for biochemical recurrence after radical prostatectomy

                    -  PSA greater than or equal to 0.2 ng/mL measured more than 6 weeks after RP.

               -  Post-radiation therapy -ASTRO-Phoenix consensus definition of biochemical
                  recurrence after radiation therapy

                    -  Nadir + greater than or equal to 2 ng/mL rise in PSA

          -  Karnofsky performance status of &gt; 50 (or Eastern Cooperative Oncology Group
             (ECOG)/World Health Organization (WHO) equivalent).

          -  Age &gt;= 18.

          -  Ability to understand a written informed consent document, and the willingness to sign
             it.

        Exclusion Criteria

          -  Unable to lie flat, still or tolerate a PET scan.

          -  Concomitant investigational therapy.

          -  Patient undergoing active treatment for non-prostate malignancy, other than skin basal
             cell or cutaneous superficial squamous cell carcinoma that has not metastasized and
             superficial bladder cancer.

          -  Contraindication to furosemide administration including prior allergy or adverse
             reaction to furosemide or sulfa drugs. (Note: This exclusion criteria can be removed
             if Furosemide is omitted as part of the PET imaging protocol if a second-generation
             scatter correction is available for the used PET device).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Hope, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Thomas Hope</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

